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Abstract
Individuals with fast nicotine metabolism typically smoke more and thus have a greater risk
for smoking-induced diseases. Further, the efficacy of smoking cessation pharmacotherapy
is dependent on the rate of nicotine metabolism. Our objective was to use nicotine metabo-
lite ratio (NMR), an established biomarker of nicotine metabolism rate, in a genome-wide
association study (GWAS) to identify novel genetic variants influencing nicotine metabo-
lism. A heritability estimate of 0.81 (95% CI 0.70–0.88) was obtained for NMR using mono-
zygotic and dizygotic twins of the FinnTwin cohort. We performed a GWAS in cotinine-
verified current smokers of three Finnish cohorts (FinnTwin, Young Finns Study, FIN-
RISK2007), followed by a meta-analysis of 1518 subjects, and annotated the genome-wide
significant SNPs with methylation quantitative loci (meQTL) analyses. We detected associ-
ation on 19q13 with 719 SNPs exceeding genome-wide significance within a 4.2 Mb region.
The strongest evidence for association emerged for CYP2A6 (min p = 5.77E-86, in intron 4),
the main metabolic enzyme for nicotine. Other interesting genes with genome-wide signifi-
cant signals included CYP2B6, CYP2A7, EGLN2, and NUMBL. Conditional analyses
revealed three independent signals on 19q13, all located within or in the immediate vicinity
of CYP2A6. A genetic risk score constructed using the independent signals showed associ-
ation with smoking quantity (p = 0.0019) in two independent Finnish samples. Our meQTL
results showed that methylation values of 16 CpG sites within the region are affected by
genotypes of the genome-wide significant SNPs, and according to causal inference test, for
some of the SNPs the effect on NMR is mediated through methylation. To our knowledge,
this is the first GWAS on NMR. Our results enclose three independent novel signals on
19q13.2. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to
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Author Summary
Nicotine metabolism rate significantly varies between individuals and affects smoking
behavior. Individuals with fast nicotine metabolism typically smoke more and thus have a
greater risk for smoking-induced diseases. Further, the efficacy of smoking cessation phar-
macotherapy is dependent on nicotine metabolism rate. Twin and family studies have
shown that genes influence nicotine metabolism; however, only a minor fraction of vari-
ance in inter-individual differences in nicotine metabolism is accounted for by known
reduced activity variants in CYP2A6, the main metabolic enzyme for nicotine. Here we uti-
lized a biomarker of nicotine metabolism (nicotine metabolite ratio, NMR) in a genome-
wide association study of three Finnish cohorts to identify novel genetic variants influenc-
ing nicotine metabolism rate. Our results enclose three independent novel signals in
CYP2A6. The detected variants explain a strikingly large fraction of variance (up to 31%)
in NMR in the study samples. A genetic risk score constructed using the independent sig-
nals predicts smoking quantity in two independent Finnish samples. Further, we enclose
evidence for plausible epigenetic mechanisms influencing NMR. With the advent of other
nicotine delivery devices than tobacco, such as e-cigarettes, the need to understand the
long-term consequences and action mechanisms of nicotine and its metabolism are of
high public health relevance.
Introduction
Nicotine is a neuro-stimulant with high addiction potential [1]. Similar to other drugs causing
dependence, nicotine increases dopamine levels in the nucleus accumbens and activates the
mesolimbic brain reward pathway [2]. Nicotine metabolism rate varies significantly between
individuals and is strongly correlated to total nicotine clearance thus altering nicotine levels
from a given intake [3]. Smokers are known to titrate their nicotine levels via cigarette con-
sumption, number and volume of puffs, and depth of inhalation, to achieve and maintain
desired levels; thus, nicotine clearance rate influences smoking behavior [4]. Individuals with
fast metabolism typically smoke more, are less likely to succeed in quitting, and are more prone
to nicotine dependence (ND) [5]. Consequently, those who smoke more have a greater risk for
smoking-induced diseases [6]. Beyond the evident toxic effects of tobacco smoke, there is
increasing evidence that, in addition to the known acute effects of nicotine [7], chronic nicotine
exposure as such may also increase the risk of cancer by multiple mechanisms [8]. With the
advent of other nicotine delivery devices than tobacco, such as e-cigarettes, the need to under-
stand the long-term consequences and action mechanisms of nicotine and its metabolism are
of high public health relevance.
A member of the cytochrome P450 family, CYP2A6, is the main metabolic enzyme for nico-
tine accounting for up to 80% of nicotine clearance [9]. A large number of distinct CYP2A6
(ENSG00000255974) alleles have been identified, including SNPs, duplications, deletions, and
conversions (www.cypalleles.ki.se/cyp2a6.htm). CYP2A6 variations have been phenotypically
grouped as slow (<50% of activity), intermediate (80% of activity), and normal (100% of
activity) metabolizers. Another member of the cytochrome P450 family, CYP2B6, has an
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approximately 10% catalytic efficiency of the CYP2A6 enzyme in vitro in nicotine c-oxidation,
and may play a minor role in nicotine clearance at higher nicotine levels [10] or in the absence
of functional CYP2A6. While CYP2A6 is expressed primarily in the liver, CYP2B6
(ENSG00000197408) is expressed at higher levels in the brain, where it may influence localized
metabolism of nicotine [11, 12]. Cytochrome P450 drug metabolizing enzymes are rarely
highlighted in genome-wide association studies (GWAS) as the allele frequencies of the func-
tional variants are low in most populations [13]. However, in 2010 a very large GWAS meta-
analysis of smoking quantity revealed associations of CYP2A6 and CYP2B6 with SNPs that are
in strong linkage disequilibrium (LD) with known functional variants [14].
Nicotine metabolism involves multiple steps and several enzymatic pathways. Up to 75% of
nicotine is converted to cotinine mainly by CYP2A6, 15% of nicotine is metabolized through
other metabolic pathways, and a minor fraction (10–15%) is excreted to urine unchanged. The
majority of cotinine is further converted to 3-hydroxycotinine exclusively by CYP2A6; up to
40% is excreted to urine as 3-hydroxycotinine while 10% is further metabolized into 3-hydro-
xycotinine-glucuronide by UGT enzymes prior to excretion. Approximately 15% of cotinine is
converted to cotinine-glucuronide by UGT enzymes, and the remaining is metabolized
through other pathways. [9]
Cotinine is a relatively stable compound with a half-life of 15–20h, and is superior as a bio-
marker of nicotine intake compared to self-reported smoking quantity (cigarettes per day, CPD)
[15]. The ratio of 3-hydroxycotinine/cotinine (i.e. nicotine metabolite ratio, NMR) is an estab-
lished biomarker of CYP2A6 activity, as well as nicotine metabolism rate, and it correlates
strongly with total nicotine clearance [3]. Twin studies suggest an important genetic contribution
to nicotine metabolism, measured using the nicotine metabolite ratio. Swan and colleagues
reported that the estimated additive genetic effects on plasma NMR were 0.67 (95% CI 0.56–
0.76), dropped to 0.61 (95% CI 0.48–0.71) after adjusting for non-genetic covariates, and further
reduced to 0.49 (95% CI 0.33–0.63) when CYP2A6 was adjusted for [16], suggesting that known
CYP2A6 variants identified at the time accounted for approximately 15–20% of NMR heritability.
In addition to the strong effect of CYP2A6 and other genetic influences, NMR is also influ-
enced by various demographic and hormonal factors. According to a recent study [17], factors
affecting NMR include ethnicity, likely due to the varying frequency of reduced activity
CYP2A6 variants among different ethnicities [13]. Other affecting factors include sex, hormone
replacement therapy, and use of estrogen containing contraceptive pills, all related to CYP2A6
being induced by estrogen [18], as well as body mass index (BMI), alcohol consumption, and
cigarette consumption [17]. Altogether these above mentioned factors were estimated to
account for approximately 8% of inter-individual variance in NMR [17].
In addition to significantly affecting smoking behavior, nicotine clearance rate has been
shown to contribute to the efficacy of cessation pharmacotherapy in various retrospective stud-
ies [19–21]. In a recent randomized prospectively NMR-stratified placebo-controlled clinical
trial, varenicline (a prescription medication for smoking cessation) was more efficacious for
normal metabolizers compared to nicotine patch [22]. Nicotine patch was equally effective in
slow metabolizers with less side-effects than in varenicline treatment, suggesting that tailored
pharmacotherapy, i.e. stratifying on NMR level, can be one approach for improving smoking
cessation rates [22]. This first clinical trial to take nicotine metabolism rate into account is a
landmark paper highlighting the importance of the metabolic component cigarette smoking
and use of other nicotine products.
GWAS using metabolites measured from serum have been highly successful in identifying
underlying genes [23, 24], highlighting the power of informative phenotypes. Our objective
was to utilize NMR, a genetically informed biomarker of nicotine metabolism, in a GWAS
meta-analysis of cotinine-verified (10ng/ml) current smokers from three Finnish cohorts to
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identify novel genetic variants influencing nicotine metabolism rate. In Caucasians, with up to
90% of individuals being normal metabolizers, a minor fraction of variance in inter-individual
differences in nicotine metabolism is accounted for by known reduced activity CYP2A6 vari-
ants. Thus, we expected that other contributing factors, such as other genes, but also novel reg-
ulators of CYP2A6 action or expression, including epigenetic mechanisms, are bound to exist.
Our data highlighted novel genetic and epigenetic influences on NMR, deepening our under-
standing on factors influencing nicotine metabolism and providing valuable guidelines for fur-
ther focused studies.
Material and Methods
Study samples
FinnTwin12. FinnTwin12 is a population-based longitudinal study of five consecutive
birth cohorts (1983–1987) of Finnish twins, designed to examine genetic and environmental
determinants of health-related behaviors [25, 26]. The study has a two-stage sampling design.
The first-stage is an epidemiological investigation, with four waves of data collection (at ages
12, 14, 17, and at early adulthood) providing data on approximately 2700 families with twins.
The second-stage is an intensive assessment of a sub-sample nested within the epidemiological
study. Most of the sub-sample is selected at random, but this random sample is then enriched
with twins from families with a history of elevated familial risk for alcoholism. The 1295 sub-
jects of the intensive sample have DNA available while serum was available on 780 subjects.
Among this sample, cotinine and 3-hydroxycotinine were measured from all self-identified
current smokers. A total of 211 subjects (55 monozygotic (MZ) individuals (one co-twin from
each MZ pair), 80 dizygotic (DZ) individuals from 40 full DZ pairs and additional 76 DZ indi-
viduals (one co-twin from each DZ pair)) with cotinine above 10ng/ml and 1000Genomes
imputed genome-wide genotype data available were included in the NMR GWAS analyses.
Genome-wide Infinium 450k Methylation BeadChip data (from whole blood DNA) were avail-
able on 157 of the NMR GWAS subjects.
FinnTwin16. FinnTwin16 is a population–based longitudinal study of five consecutive
birth cohorts (1975–1979) of Finnish twins and their families [25, 26]. Initially, 3065 families
(6130 twins) were contacted, with a 91% response rate. Questionnaire assessments including
detailed alcohol and smoking data were conducted on twins as they reached the ages of 16, 17,
18½, and young adulthood (ages 22–25). For an intensive study on predictors of alcoholism,
both twin pairs with very similar alcohol use and twin pairs with dissimilar alcohol use were
identified [27, 28]. Additionally, some randomly picked twin pairs functioning as a control
group were selected. The 602 subjects of the intensive sample have DNA and serum available.
Among this sample, cotinine and 3-hydroxycotinine were measured from all self-identified cur-
rent smokers, and 174 subjects (40 MZ individuals (one co-twin from each MZ pair), 76 DZ
individuals from 38 full DZ pairs, and additional 58 DZ individuals (one co-twin from each DZ
pair)) with cotinine above 10ng/ml and 1000Genomes imputed genome-wide genotype data
available were included in the NMRGWAS analyses. Genome-wide Infinium 450k Methylation
BeadChip data (from whole blood DNA) were available on 14 of the NMR GWAS subjects.
The Young Finns Study (YFS). The Young Finns Study (YFS) is a large follow-up study of
cardiovascular risk factors from childhood to adulthood [29]. In total, 3596 children and adoles-
cents aged 3–18 from all around Finland participated in the baseline study in 1980; they were
followed up after, 3, 6, 9, 12, 21, 27, and 30 years, with comprehensive risk factor assessments,
including smoking status and alcohol use. Cotinine and 3-hydroxycotinine were measured from
all self-identified current smokers with available serum samples, and 714 subjects with cotinine
above 10ng/ml and 1000Genomes imputed genome-wide genotype data available were included
A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism
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in the NMR GWAS analyses. For 166 subjects with repeated serum samples as current smoker,
i.e. longitudinal metabolite data the NMR was assessed at the time of heaviest regular smoking
(i.e. when cotinine was highest), although NMR can be used in light regular smokers [30].
The FINRISK. The FINRISK studies are population surveys of the Finnish adult popula-
tion conducted every five years since 1972 [31], examining risk factors of chronic diseases. The
FINRISK2007 study consists of 6258 men and women aged 25–74 years drawn from the
national population register in five large geographical areas in Finland at the end of 2006. The
sample was stratified by sex, 10-year age category, and area. FINRISK2007 includes a smoking-
specific questionnaire given to a subsample of ever-smokers who attended an in-person clinical
examination and blood draw. Cotinine and 3-hydroxycotinine were measured among self-
identified current smokers and recent quitters as part of an analysis of the validity of self-
reported smoking status. A total of 419 subjects with cotinine above 10ng/ml and
1000Genomes imputed genome-wide genotype data available were included in the NMR
GWAS analyses. For scrutiny of linkage disequilibrium (LD) patterns and allele frequencies, as
well as for Genetic Risk Score analyses, additional non-overlapping samples from FINRISK
cohorts 1992, 1997, 2002, and 2007 (N = 19857 after individuals with pi-hat>0.4 were
excluded; cotinine and 3-hydroxycotinine not available in these) with 1000Genomes imputed
genome-wide genotype data available were used.
The NAG-FIN. The NAG-FIN sample was ascertained from the Older Finnish Twin
Cohort consisting of adult twins born in 1938–1957. Based on earlier questionnaires, twin
pairs concordant for ever-smoking were recruited along with their family members (mainly
siblings) for the Nicotine Addiction Genetics (NAG) consortium [32]. Data collection took
place in 2001–2005. A total of 747 families including 2193 subjects were assessed by DNA sam-
ple collection, structured psychiatric interview, and additional questionnaires, yielding detailed
phenotypes of lifetime smoking behavior (including initiation, quantity, and cessation). For the
Genetic Risk Score analyses 2054 subjects from 745 families (including 141 MZ twins (one co-
twin from each MZ pair), 856 DZ individuals from 428 full DZ pairs, additional 147 DZ indi-
viduals (one co-twin from each DZ pair), 50 individuals of unknown zygosity, and 860 other
family members (mainly siblings)) with 1000Genomes imputed genome-wide genotype data
were used. Serum samples for cotinine and NMR analyses were not collected.
Ethics permissions
Written informed consent, according to the current edition of the Declaration of Helsinki, was
obtained from all subjects who were interviewed and/or gave DNA samples before the begin-
ning of the studies. The collection of blood samples followed the recommendations given in
the Declaration of Helsinki and its amendments. For the FinnTwin12, FinnTwin16, and
NAG-FIN studies, data collection has been approved by the hospital district of Helsinki and
Uusimaa, the ethics committee for epidemiology and public health (HUS-113-E3-01, HUS-
346-E0-05, HUS 136/E3/01). FinnTwin12 and FinnTwin16 have also been approved by the
IRB of Indiana University at Bloomington, Indiana, while NAG-FIN was also approved by the
IRB of Washington University (St. Louis). Young Finns Study data collection has been
approved by the hospital district of Southwest Finland ethics committee (ETMK: no. 88/180/
2010). The ethics approvals for FINRISK have been obtained from the Coordinating Ethics
Committee of Helsinki and Uusimaa Hospital District.
Phenotypes and covariates
Cotinine and 3-hydroxycotinine phenotypes were measured from frozen serum samples using
liquid chromatography/tandem mass spectrometry (University of Toronto, prof. Rachel
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Tyndale’s laboratory) for the FinnTwin12, FinnTwin16, and YFS samples, as previously
described [33], and using gas chromatograph-mass spectrometer (at the National Institute for
Health and Welfare, Helsinki, Finland) for the FINRISK2007 sample, as previously described
[34]; these assays for NMR were demonstrated to be fully concordant (R2 = 0.93, P<0.0001)
[35]. Cotinine threshold of10ng/ml was applied to restrict the analyses to regular smokers.
Several potential factors influencing on NMR (sex, age, BMI, smoking quantity, alcohol con-
sumption, genotyping batch) [17] were considered as covariates. Sex and BMI were associated
with NMR (p<0.05) in the initial linear univariate regression models, and were selected as
covariates for the study specific GWAS. Further, age was selected as a covariate due to the sam-
pling design of the population-based samples. Neither smoking quantity, alcohol consumption,
nor genotyping batch, were significant confounders (p>0.05) and thus were not included as
covariates. Details of phenotype and covariate distributions in the three samples are presented
in Table 1.
Genotyping and imputation
Genotyping was performed with the Human670-QuadCustom Illumina BeadChip at the Wel-
come Trust Sanger Institute, and with the Illumina Human Core Exome BeadChip at the Wel-
come Trust Sanger Institute and at the Broad Institute of MIT and Harvard. Standard post-
genotyping quality control thresholds were applied for SNPs (minor allele frequency (MAF)
<0.01, SNP call rate<0.95, and Hardy Weinberg Equilibrium (HWE) p<1E-06). Further, sub-
jects with a call rate<0.95 were excluded, and a sample heterozygosity test, as well as sex and
Multidimensional Scaling (MDS) outlier checks were done. Pre-phasing of the data was done
with SHAPEIT2 [36] and imputation with IMPUTE2 [37] using the 1000 Genomes Phase I
integrated haplotypes (produced using SHAPEIT2) reference panel [38]. For data generated
with the Human670-QuadCustom Illumina BeadChip the following post-imputation exclusion
criteria were applied for SNPs: MAF<0.01, SNP call rate<0.95 (<0.99 for SNPs with
MAF<0.05), HWE p<1E-06, and imputation info<0.4. For data generated with the Illumina
Human Core Exome BeadChip the SNP exclusion criteria were otherwise identical, except that
a threshold of minor allele count<2 was applied instead of a MAF cut-off. Further, the same
sample quality thresholds as in post-genotyping quality control were applied. Quality controls
and imputation for all Finnish GWAS data were done centrally at the Institute for Molecular
Medicine, University of Helsinki, Helsinki, Finland.
Statistical analyses
Twin modelling. Altogether 81 DZ twin pairs (32 same-sex and 49 opposite-sex) and 54
MZ twin pairs with cotinine (>10 ng/ml in both co-twins) and 3-hydroxycotine measures
Table 1. Phenotype and covariate proportions (%) andmeans (min-max, SD) in the FinnTwin, Young Finns Study (YFS), and FINRISK2007
samples.
FinnTwin (N = 385) YFS (N = 714) FINRISK2007 (N = 419)
% male 50% 54% 54%
Age 24 (21–30, 2.0) 30 (15–45, 8.6) 49 (25–74, 12.8)
BMI 24 (16–43, 4.0) 24 (16–46, 3.9) 27 (16–50, 5.0)
CPD 11 (1–40, 5.9) 13 (1–64, 7.6) 13 (0–40, 8.4)
Cotinine (ng/ml) 182 (10–656, 122.5) 185 (11–577, 112.4) 170 (24–610, 94.7)
3-hydroxycotinine (ng/ml) 70 (1–275, 48.2) 77 (1–435, 55.0) 60 (4–293, 40.7)
NMR 0.4 (0.01–1.6, 0.22) 0.5 (0.01–1.7, 0.24) 0.4 (0.04–2.0, 0.21)
doi:10.1371/journal.pgen.1005498.t001
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available in the FinnTwin12 and FinnTwin16 samples were used to estimate the heritability of
NMR. Intraclass correlations were calculated and quantitative genetic modelling was used to
estimate alternative variance components models in Mx [39]. We evaluated the presence of
additive genetic (A), genetic effects due to dominance (D), shared environmental effects (C),
and environmental effects not shared by twins (E).
Power analyses. We estimated the power of our GWAS meta-analysis sample to detect
signals at the p<5E-08 significance threshold assuming an LD (r2) of 0.8 between the causal
allele and the marker allele, as previously suggested [40]. To account for intraclass correlation
within 78 DZ pairs included in the FinnTwin sample, we estimated the effective sample size
(Neff) for these 156 DZ twins using the formula Neff = N/(1 + (m ‐ 1)ICC), where N is the num-
ber of DZ twins (156 twins in our case), m is the number of observations in a group (2 in our
case), and ICC is the intraclass correlation (0.26 estimated from FinnTwin data), resulting in
an estimated effective sample size of 124 (a reduction of 32). Thus, the effective sample size in
our meta-analysis was reduced from 1518 to 1486. We performed power analyses using the
Genetic Power Calculator [41].
GWAS analyses. Prior to the analyses NMR was transformed using rank transformation
to obtain a normal distribution. The transformation was employed with the rntransform()
function available in the R statistical software package GenABEL [42], which replaces the
median NMR value with the value zero and transforms the rest of the values so that they are N
(0,1)-normally distributed around this value. NMR distributions before and after the transfor-
mation are shown in S1 Fig.
GWAS analyses were done using GEMMA (Genome-wide efficient mixed-model associa-
tion) [43], separately for FinnTwin (FinnTwin12 and FinnTwin16 samples were pooled
together), Young Finns Study, and FINRISK2007 cohorts. Allelic dosage data were used to
account for genotype uncertainties. The genetic associations were acquired with a linear mixed
model in which the rank transformed NMR was the dependent variable and the coded allele
dose (represented by the posterior mean genotypes) was the independent variable. The model
included age, sex, and BMI as covariates (fixed effects). In addition, population stratification
and relatedness within the sample were accounted for by the covariance matrix of the random
effect in the model. The covariance matrix was determined by a relatedness matrix, calculated
from genome-wide genotype data and representing genetic similarity across individuals. An
estimate of the genomic control inflation factor (λ) was calculated for all three cohorts with the
estlambda() function of the R library GenABEL [42]. P-values below 5E-08 were considered as
genome-wide significant.
GWASmeta-analysis. Meta-analysis was performed with the software META [44]. The
fixed effects model, using the inverse variance method, was chosen as all cohorts had the same
phenotype and measurement scale. Briefly, the cohort-specific beta estimates were summed
together by weighting the cohort-specific beta estimates by the inverse of their variance in order
to take into account the contribution of each cohort. In addition, the variances of the cohort-
specific beta estimates were first multiplied by the cohort-specific genomic control λ estimates.
A total of 8970401 SNPs were included in the meta-analysis (the number of SNPs in the cohort-
specific GWAS analyses was 9087865 in FinnTwin, 8829569 in YFS, and 9050503 in FIN-
RISK2007). The genomic control inflation factor (λ) in the meta-analysis was 1.027, while in
cohort-specific GWAS they were 1.038 in FinnTwin, 1.016 in YFS, and 1.000 in FINRISK2007.
Conditional analyses. Genomic loci reaching genome-wide significance in the meta-anal-
ysis were further targeted with conditional analyses to estimate the number of independent sig-
nals. We ran association analyses separately in each of the three cohorts conditioning on our
SNP with the lowest p-value, followed by a meta-analysis of the three cohorts. The next signal
was identified from the conditional meta-analysis results, and included in the second round of
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conditional analyses. This process was repeated in an iterative fashion until no residual
genome-wide significant signal (p<5E-08) remained.
After conditioning on the top-SNP (rs56113850), rs113288603 emerged as the second inde-
pendent SNP. As this SNP showed no association in either the cohort-specific GWAS or in
meta-analysis, we further scrutinized the plausible interplay between rs56113850 and
rs113288603 within the largest of our cohorts (YFS), by testing how adding the other SNP or
an interaction term (rs56113850rs113288603) to the model affects the effect sizes.
Percentage of variance explained by the SNPs. Percentage of variance in rank trans-
formed NMR explained by the independent SNPs, as well as the known CYP2A6 alleles
[CYP2A62 (= rs1801272), CYP2A69 (= rs28399433), CYP2A614 (= rs28399435),
CYP2A618 (= rs1809810), CYP2A621 (= rs6413474), allele naming according to the CYP2A6
Allele Nomenclature (www.cypalleles.ki.se/cyp2a6.htm)) included in our 1000Genomes
imputed data set, was estimated by running linear regression models separately in each of the
three cohorts, with NMR as the dependent variable and age, sex, BMI, and SNPs as explanatory
variables. The variance explained by a specific SNP or SNPs was acquired by subtracting the R2
from the model including only the covariates (age, sex, BMI) from the R2 of the model includ-
ing also the SNP/SNPs of interest as explanatory variables.
Genetic risk score analyses. We constructed 3-SNP weighted genetic risk scores (wGRS)
using the independent 19q13.2 SNPs from the meta-analysis (rs56113850, rs113288603,
esv2663194) by summing the number of major alleles (0/1/2) for each of the three SNPs
weighted by their estimated effect sizes obtained from the GWAS meta-analysis. In addition, a
4-SNP wGRS comprising of the four independent SNPs in FINRISK2007 (rs56113850,
rs113288603, esv2663194, rs12461964) was constructed. We then tested whether the wGRSs
predict smoking behavior using two independent Finnish samples. In the FINRISK sample (no
overlap with the FINRISK2007 sample used in NMR GWAS), logistic regression was used to
model current daily (N = 3138) vs. former (abstinence of6 months; N = 2710) smoking, and
hurdle regression was used to model smoking quantity among current smokers (quantitative
CPD; N = 3138). In the family-based NAG-FIN sample, mixed effects logistic regression was
used to model current daily (N = 816) vs. former (abstinence of6 months; N = 833) smoking,
and a mixed effects poisson regression was used to model smoking quantity among current
smokers (quantitative CPD; N = 816). Odds ratios (ORs) obtained for current vs. former smok-
ing depict whether it is more (OR>1) or less (OR<1) likely to fall into category of ‘former
smoker’ as wGRS increases. Regression coefficients (betas) obtained for smoking quantity indi-
cate the increase (positive beta) or decrease (negative beta) in CPD as wGRS increases. All anal-
yses were adjusted for age, sex, and BMI, and families were assumed to form clusters in the
NAG-FIN sample. Finally, a meta-analysis of the two samples was performed. Additionally, we
utilized available questionnaire data of potential confounders of cessation. In a sensitivity anal-
ysis we excluded (i) 62 (7.4%) NAG-FIN former smokers who report quitting due to adverse
health effects, and (ii) 188 (23%) current and 176 (21%) former smokers who reported having
a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) major depres-
sive disorder diagnosis. For FINRISK we excluded 820 (26%) current smokers and 775 (29%)
former smokers who either (i) reported having a diagnosis of cancer of cardiovascular disease
(angina pectoris, heart failure, asthma, pulmonary emphysema, or bronchitis), (ii) reported
being on a disability pension, or (iii) reported self-rated health as ‘poor’ or ‘very poor’. Further,
we adjusted the analyses for alcohol use, a known confounder, i.e. factor associated with both
NMR and smoking behavior (grams of ethanol consumed during the last week in FINRISK,
and grams of ethanol consumed on average per week in NAG-FIN). We also ran additional
wGRS analyses with an rs56113850rs113288603 interaction term included as a covariate, to
account for the detected interplay between these two SNPs. As four independent SNPs emerged
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in the FINRISK2007 GWAS sample, and the main wGRS sample was derived from FINRISK
cohorts, we report results for the 4-SNP wGRS; however, the 3-SNP wGRS analyses yielded
highly similar results.
Annotation. For annotation of the plausible role of the highlighted SNPs, we considered
three alternative hypotheses: (A) SNPs directly affect the function of CYP2A6 enzyme, or are in
LD with functional variants, resulting in changes in NMR, (B) DNAmethylation mediates the
effect of SNPs on NMR, and (C) NMRmediates the effect of SNPs on methylation. To test
hypothesis A, the potential functional consequences of the associating SNPs were predicted using
the Ensembl Variant Effect Predictor database (http://www.ensembl.org/index.html) (includes
predictions PolyPhen and SIFT). LD patterns were estimated by using the ‘solid spine of LD’
method of the program Haploview [45] from GWAS data generated in the FINRISK 1992, 1997,
2002, and 2007 cohorts (N = 19857). Similarly, minor allele frequencies representative of the
Finnish population were obtained from the FINRISK sample (N = 19857). To test hypotheses B
and C we proceeded with methylation quantitative loci analyses and Causal Inference Test (CIT).
Methylation quantitative trait loci (meQTL) analyses. In order to test whether the 719
genome-wide significant SNPs affect methylation we performed meQTL analyses. Methylation
probes targeting CpG sites within the 4.2 Mb target region (i.e. the region with genome-wide sig-
nificant association signal) with 500 kb flanking regions were identified from the Infinium
HumanMethylation450 BeadChip (Illumina) data available in 171 FinnTwin12 and FinnTwin16
subjects included in the NMRGWAS. Array preprocessing and normalization was performed
using the Bioconductor package ‘minfi’ [46], with Stratified Quantile Normalization using the
function PreprocessQuantile. Altogether 2268 methylation probes map to the 4.2 Mb target
region; 844 of these were excluded as they have been reported as unreliable based on various crite-
ria (mapping to multiple genomic locations and known repeat regions, containing SNPs, etc.)
[47]. Variance in methylation levels was estimated in the remaining 1424 CpG sites; as we had a
limited sample size (N = 171) and thus limited power to detect association, we restricted the
meQTL analyses to 158 CpG sites with reasonable variance (interquartile range0.05; S2 Fig).
We constructed linear regression models of DNAmethylation levels at each CpG site as the
dependent variable and dosage of coded allele at each SNP as the explanatory variable while
adjusting for age and sex, as previously suggested [48, 49]. To account for multiple testing we used
the Benjamini and Hochberg method [50] and considered false discovery rate (FDR) corrected p-
values below 0.05 as statistically significant. Five CpG sites mapped to CYP2A6 in the genome-
wide methylation data; however, we were unable to scrutinize these as four probes were filtered
out based on the quality control criteria and the fifth probe had a low (0.02) interquartile range.
Causal Inference Test (CIT). We proceeded with a CIT with the 16 CpG sites highlighted
in the meQTL analyses to establish the direction of relationship between a causal factor (G,
genotype), a potential mediator (M, methylation), and an outcome (Y, NMR). Briefly, the con-
ditions for CIT are (1) G and Y are associated, (2) G is associated with M after adjusting for Y,
(3) M is associated with Y after adjusting for G, and (4) G is independent of Y after adjusting
for M [51]. We performed CIT using the R script provided by Millstein and colleagues [51].
This CIT R script gives a formal p-value for causal model (‘DNAmethylation mediates the
effect of SNPs on NMR’), reactive model (‘NMRmediates the effect of SNPs on methylation’),
and a causal call based on the two p-values obtained. To account for multiple testing we consid-
ered FDR corrected p-values below 0.05 as statistically significant.
Results
MZ and DZ twins of the FinnTwin12 and FinnTwin16 cohorts were used to provide heritabil-
ity estimates for NMR. The intraclass correlation for NMR was 0.80 for MZ and 0.26 for DZ
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pairs. The pattern of correlations suggested that in addition to additive genetic effects, domi-
nance effects may be present but shared environmental were unlikely to be present. The data
were consistent with both AE and ADE models, but not the ACE model as the MZ correlation
was much larger than twice the DZ correlation (in such a situation the C component will be
zero). In the AE model, A effects accounted for 0.81 (95% CI 0.70–0.88) of variance in NMR.
The ADE model fit difference was not statistically significant from the more parsimonious AE
model (p = 0.087, Δχ2 = 2.94, Δdf = 1); in the ADE model A effects accounted for 0.20 (95%CI
0.00–0.85) and D effects for 0.62 (95%CI 0.00–0.88) of the variance in NMR.
According to the power analyses we had inadequate power to detect signals with rare SNPs
(MAF<5%) unless they have very large effect sizes, but high power to detect signals with com-
mon SNPs (MAF>5%) that have medium to high effect sizes (beta>±0.6) (S1 Table).
Each of the three Finnish cohorts independently showed genome-wide significant associa-
tion on 19q13.2. In our GWAS meta-analysis 719 SNPs exceeded the genome-wide significance
threshold within a 4.2 Mb region on 19q13.2 (chr19:39546965–43710562; according to
GRCh37/hg19) (S2 Table). Manhattan and QQ plots are presented in Figs 1 and 2. The stron-
gest evidence for association emerged for CYP2A6 (minimum p = 5.77E-86 for rs56113850, in
intron 4) (S3 Table). Other genes of relevance with genome-wide significant signals included
CYP2B6 (minimum p = 1.95E-24 for rs7260329, in intron 8), CYP2A7 (ENSG00000198077)
(minimum p = 1.43E-38 for rs28602288, beta = -0.48, -83C>T, within predicted promoter
region), EGLN2 (ENSG00000269858) (minimum p = 7.87E-16 for rs76443752, in intron 3),
and NUMBL (ENSG00000105245) (minimum p = 1.40E-20 for rs4802082, in intron 5) (S2
Table).
Conditional analyses of the 19q13.2 locus revealed three independent genome-wide signifi-
cant signals tagged by rs56113850, rs113288603, and esv2663194 (Fig 3 and Table 2). The same
independent SNPs emerged in all the three cohorts. A fourth independent signal (rs12461964)
emerged in the conditional analysis of the FINRISK2007 sample; however, this was not seen in
the meta-analysis of the three samples. All the independent SNPs are imputed, and are located
either within CYP2A6 or at most at a distance of 8 kb from the gene. For all the independent
SNPs the minor allele decreases NMR, i.e. decreases nicotine clearance rate (Table 2). None of
the independent SNPs have predicted functional effects.
A plausible interplay between the top-SNP rs56113850 and rs113288603 was detected.
When analysed within the largest of our cohorts (YFS) the minor allelic effect size of
rs113288603 increased from non-significant (beta = 0.05, p = 0.522) to highly significant (beta
= -0.47, p = 1.32E-09) when rs56113850 was added to the model; when an interaction term
(rs56113850rs113288603) was also added to the model the effect size further increased (beta =
-0.62, p = 1.32E-03). Similarly, the effect size of rs56113850 increased from -0.67 (p<2E-16) to
-0.83 (p<2E-16) when rs113288603 was added to the model; addition of an interaction term
(rs56113850rs113288603) to the model did not further affect the results (beta = -0.82, p<2E-
16).
According to LD estimation in the large FINRISK sample (N = 19857), rs56113850 and
rs12461964 share an LD block with the known reduced activity allele CYP2A62, and
esv2663194 shares a block with the known reduced activity allele CYP2A69, while
rs113288603 is located outside these LD blocks (S5 Fig). Based on pairwise LD values both
CYP2A62 and CYP2A69 exhibit strong LD with all four independent SNPs (S4 Table), and
after conditioning on the top-SNP (rs56113850) neither were genome-wide significant (S5
Table).
Age, sex, and BMI explained altogether 8.9%, 6.1%, and 0.53% of the variance in NMR in
FinnTwin, YFS, and FINRISK2007 samples, respectively. The top-SNP rs56113850 alone
explains 14–23% of the variance in NMR in the three cohorts (Table 2). Further, the percentage
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Fig 1. QQ plot of the GWASmeta-analysis results of the three Finnish cohorts (λ = 1.027).
doi:10.1371/journal.pgen.1005498.g001
Fig 2. Manhattan plot of the GWASmeta-analysis results of the three Finnish cohorts. The horizontal line represents the genome-wide
significance threshold (p<5E-08).
doi:10.1371/journal.pgen.1005498.g002
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Fig 3. Regional plot of 19q13.2. (A) In the GWASmeta-analysis a minimum p-value of 5.77E-86 was obtained for rs56113850, in intron 4 of CYP2A6. (B)
Analyses conditioned on the top-SNP (rs56113850) revealed rs113288603 as a second independent genome-wide significant signal (pcond = 7.03E-25). (C)
Analyses conditioned on the two independent SNPs (rs56113850, rs113288603) revealed esv2663194 as a third independent genome-wide significant
signal (pcond = 9.3E-17). (D) Analyses conditioned on the three independent SNPs yielded no additional signal exceeding the genome-wide significance
threshold. All plots are generated with LocusTrack [52]. LD (R2) values were obtained from the FINRISK sample (N = 19857).
doi:10.1371/journal.pgen.1005498.g003
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of variance explained by the three independent SNPs (rs56113850, rs113288603, and
esv2663194) when jointly included in the model was 20.8% in FinnTwin, 31.4% in YFS, and
26.3% in FINRISK (increasing to 27.7% when rs12461964 was included).
In the wGRS analyses highly similar results were obtained for the 3-SNP and 4-SNP wGRSs;
only results for the 4-SNP wGRS are presented. For ease of interpretation, the wGRS was con-
structed as a weighted sum of major alleles (all of which increase nicotine clearance rate). In
the wGRS meta-analysis of 3954 current smokers statistically significant association was
detected for quantitative CPD (beta = 0.10, 95% CI 0.04–0.16, p = 0.0019), suggesting that indi-
viduals with faster metabolism smoke more. The wGRS meta-analysis for current (N = 3954)
vs. former (N = 3543) smoking showed association with increased likelihood of being a former
smoker (OR = 1.39, 95% CI 1.09–1.76, p = 0.007). Similarly, the major allele of CYP2A62
showed a trend of association with increased likelihood of being a former smoker (OR = 1.03,
95% CI 0.72–1.47, p = 0.89), although the results were not statistically significant. To scrutinize
potential confounders for cessation, we utilized available questionnaire data and excluded
NAG-FIN individuals who either have a DSM-IV major depression disorder diagnosis or
report quitting due to adverse health consequences and FINRISK individuals who have a rele-
vant somatic diagnosis, are on disability pension, or rate their health as ‘poor’. Further, we
adjusted the analyses for alcohol consumption. After these exclusions, 2946 current and 2591
former smokers remained, and the wGRS result no longer was statistically significant
(OR = 1.30, 95% CI 0.95–1.78, p = 0.10). We also tested these models with the
rs56113850rs113288603 interaction term included as a covariate; in all the models the interac-
tion term was non-significant (p>0.05) and so a more complex model was not justified.
In the meQTL analyses of the 719 genome-wide significant SNPs and 158 CpG sites within
the target region, methylation values of 16 CpG sites showed statistically significant association
with 173 of the SNPs (FDR corrected p<0.05) (S6 Table). Among the highlighted genes were
EGLN2, CYP2A7, CYP2F1 (Cytochrome P450, Family 2, Subfamily F, Polypeptide 1)
(ENSG00000197446), and DLL3 (Delta-like 3 (Drosophila)) (ENSG00000090932) (S7 Table).
To distinguish between our hypotheses B (‘SNPs affect NMR via methylation’) and C (‘SNPs
affect methylation via NMR’) we performed CIT, and confirmed that methylation at the CpG
site tagged by cg08551532 (in DLL3) mediates the effect of SNPs on NMR (S8 Table). We
detected no evidence supporting hypothesis C.
Discussion
Nicotine metabolism rate is one of the key factors affecting smoking behavior, and has also
been shown to contribute to the efficacy of cessation pharmacotherapy [22]. Many smokers
find it exceedingly difficult to succeed in quitting, even when they have a major cardiovascular
illness and smoking cessation would greatly improve their prognosis [53]. Current pharmaco-
therapies and behavioral counselling enhance smoking cessation rate on average by only
approximately 2-fold [54], highlighting the need for more effective cessation support. Unravel-
ing the genetic architecture of nicotine metabolism may enhance development of tailored
smoking cessation pharmacotherapies.
MZ and DZ twins of FinnTwin12 and FinnTwin16 cohorts yielded a heritability estimate of
0.81 for NMR, confirming that genetic effects are major determinants of inter-individual vari-
ance in NMR. This estimate is higher than previous estimates obtained in an experimental set-
ting [16], perhaps due to less heterogeneity in the Finnish sample. Our aim was to identify
novel genetic variants affecting nicotine metabolism. We utilized NMR, a biomarker of nico-
tine metabolism, in a GWAS meta-analysis of three Finnish cohorts, and identified association
on 19q13.2. This locus harbours a number of genes, including several members of the
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cytochrome P450 gene family. Three independent genome-wide significant signals were
detected, all located either within or in the immediate vicinity of CYP2A6, the gene encoding
the main metabolic enzyme for nicotine. A fourth independent signal in CYP2A6 emerged in
one of the samples (FINRISK2007); however, this was not seen in the meta-analysis. The
minor alleles of all of the independent variants associated with decreased NMR values, i.e.
decreased nicotine clearance rate. All the independent variants are novel signals and have not
been previously been highlighted in any smoking-related GWAS.
Our top-SNP (rs56113850) is located in intron 4 of CYP2A6, has a high minor allele fre-
quency (MAFFINRISK = 0.44) and a prominent effect size (beta = -0.65), and alone accounts for
a substantial percentage of variance (14–23%) in NMR in the three Finnish cohorts. Our sec-
ond independent SNP (rs113288603) is located 5.9 kb upstream of CYP2A6, seems to be
enriched in the Finnish population (MAFFINRISK = 0.15 vs. MAFEUR = 0.09), has a small effect
size (beta = -0.02), and accounts for less than 1% of variance in NMR in the three cohorts. Nei-
ther of these variants has predicted functional consequences. Interestingly, our data support a
plausible interplay between rs113288603 and rs56113850, as the effect sizes significantly
increase when the other SNP is added to the model. These findings are in line with our GWAS
data, as rs113288603 shows no association in any of the cohort-specific GWAS or in the meta-
analysis, but in an analysis conditioned on rs56113850 it emerges as the second independent
genome-wide significant SNP. The plausible mechanism underlying the interplay remains to
be determined.
Our third independent variant (esv2663194) tags a 32 kb deletion that affects both CYP2A6
and CYP2A7. Esv2663194 has a low minor allele frequency (MAFFINRISK = 0.03) and a promi-
nent effect size (beta = -1.08), and accounts for 3–8% of variance in NMR in the three cohorts.
The 32 kb (chr19:41355715–41387669, according to GRCh37/hg19) deletion abolishes exons
1–2 in CYP2A6 and exons 2–9 in CYP2A7 when compared to the reference sequence; both
genes have multiple isoforms and the consequence of the deletion varies between the isoforms.
The 32 kb deletion may produce a similar construct as CYP2A612, which is a hybrid allele
formed by an unequal crossover between CYP2A6 and CYP2A7. CYP2A612 is composed of
the 50-regulatory region and exons 1–2 of CYP2A7 and exons 3–9 and the 30-regulatory region
of CYP2A6, and harbors 10 amino acid differences when compared to the wild-type CYP2A6
allele, with an allele frequency of 2.2% reported among Spaniards [51]. CYP2A612 is shown to
have reduced enzyme activity in vivo [55, 56]; in line with this, the minor allele of esv2663194
associates with decreased clearance rate. Further studies are needed to confirm whether the 32
kb deletion tagged by esv2663194 indeed creates a construct with properties similar to
CYP2A612.
Our fourth independent SNP (rs12461964; detected in the FINRISK2007 sample) is located
8.2 kb downstream of CYP2A6, has a high minor allele frequency (MAFFINRISK = 0.45) and a
prominent effect size (beta = -0.61). Rs12461964 is in high LD with the top-SNP rs56113850
(D’ = 0.85); although it was identified as an independent SNP in conditional analyses in the
FINRISK2007 sample, the detected association likely reflects LD with rs56113850.
To date, the most widely studied CYP2A6 variants include CYP2A62 (rs1801272, L160H)
which encodes a catalytically inactive enzyme, a whole gene deletion allele CYP2A64,
CYP2A69 (rs28399433, -48T>G), which has an alteration in the TATA box resulting in lower
expression of a structurally normal protein, and CYP2A612 discussed above [13]. Of these
characterized reduced-activity variants, our data included CYP2A62 and CYP2A69, both of
which showed genome-wide significant association but were not identified as independent sig-
nals in conditional analyses. A previous very large (N = 85997) meta-analysis of self-reported
CPD showed genome-wide significant association on 19q13.2, with strongest evidence
obtained for rs4105144, which is in LD with CYP2A62 (D0 = 1.0 in CEU) [14]. Similarly, LD
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between our novel independent signals and both CYP2A62 and CYP2A69 was high (D’ =
0.89–1.00). The percentage of variance in NMR explained by CYP2A62 and CYP2A69 in our
study cohorts was up to 6% and 12%, respectively. A previous study using an ethnically diverse
sample suggested that 15–20% of variance in NMR is accounted for by the four characterized
reduced-activity variants (CYP2A62, CYP2A64, CYP2A69, and CYP2A612) [16]; much of
the genetic variation would not have been tested for in this study (i.e. CYP2A610 –35). Inter-
estingly, in our study CYP2A69 alone explained a large fraction of variance in NMR, possibly
due to the higher minor allele frequency in the Finnish cohorts (MAF 0.12–0.14) compared to
that reported in the Caucasian population (MAFEUR = 0.07). In addition to CYP2A62 and
CYP2A69, our data set included three additional known alleles, CYP2A614 (rs28399435;
S29N), CYP2A618 (rs1809810; Y392F), and CYP2A621 (rs6413474; K476R). Although they
are non-synonymous variants, their effect on nicotine clearance likely is minimal. CYP2A614
does not appear to affect enzyme activity [57, 58], and although CYP2A618 has a decreased
activity towards another substrate, coumarin, activity towards nicotine is unaffected [59].
Based on in vivo studies, CYP2A621 showed normal activity in a Caucasian population [60].
After conditioning on our top-SNP (rs56113850), none of the five known alleles were genome-
wide significant, suggesting that rs56113850 captures information on all of these alleles.
The percentage of variance explained by our novel independent SNPs was very high (up to
31%), exceeding the estimates for the four functional variants frequently genotyped in Cauca-
sians [16]. Our novel variants likely tag multiple functional variants, both known and unidenti-
fied ones, and thus capture information on relevant haplotypes. The population-attributable
effect of the novel independent variants thus is far greater than that of the known functional
variants, and for the purpose of estimating the rate of nicotine metabolism our novel SNPs are
more informative than the known previously characterized reduced-activity variants.
Based on our twin modelling, the heritability of NMR is 0.81. Although our novel indepen-
dent SNPs capture a strikingly large fraction of this, major fraction still remains unaccounted
for. This may be due to limitations of GWAS with lack of coverage of CYP2A6 duplications,
translocations, and rare variants. Further, the high sequence homology between CYP2A6,
CYP2A7, and CYP2A13may prohibit detection of variants within homologous regions. SNP
genotyping technologies using short probes will not be able to detect these variants with high
specificity; most likely such variants will fail the HWE threshold, and thus will be excluded
from analyses. In addition, limitations of statistical power result in inability to detect all rele-
vant signals. In our GWAS meta-analysis we had high power to detect signals with common
SNPs (MAF>5%) that have medium to high effect sizes. This is reflected in our top-SNPs,
three of which are not only common but also have large effect sizes, and one that is rare
(MAF = 0.03) but has a large effect size (beta = -1.08). We had very low power to detect signals
with rare SNPs that have low effect sizes, and it is likely that we missed those signals; larger
studies are needed to capture these signals.
Ethnicity has been reported as a prominent factor affecting NMR; however, all the subjects
in the current study were Caucasian (Finns). Age, sex, and BMI accounted for 8.9% and 6.1%
of variance in NMR in the FinnTwin and YFS samples, respectively. This is in line with a previ-
ous study showing that various non-genetic factors account for altogether 8% of inter-individ-
ual variance in NMR [17]. However, in the FINRISK2007 sample age, sex, and BMI only
accounted for 0.5% of variance in NMR, which may be due to older age and longer overall
duration of smoking with more cessation than among the young adult FinnTwin and YFS
samples.
Although only variants in CYP2A6 were highlighted as independent signals, other interest-
ing genes, such as CYP2B6, CYP2A7, EGLN2, and NUMBL, reside within the 19q13 locus, and
showed genome-wide significant association in our GWAS meta-analysis. Our top-SNP in
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CYP2B6 (rs7260329) has been highlighted in the large GWAS meta-analysis of CPD [14].
CYP2B6 can also catalyze nicotine metabolism to cotinine and to nornicotine [9]; the CYP2B6
gene sits adjacent to CYP2A6 and they share some common regulation. CYP2B6 also metabo-
lizes several other drugs of abuse, as well as bupropion, an atypical antidepressant also used as
a smoking cessation aid [5]. Several functional CYP2B6 variants have been identified. The most
prevalent and clinically important variant is CYP2B66, characterized as a haplotype consisting
of two linked non-synonymous variants CYP2B64 (rs2279343 (K262R)) and CYP2B69
(rs3745274 (Q172H)), resulting in a splice site variant with reduced function [61]. In the cur-
rent study the non-synonymous SNPs defining CYP2B64, CYP2B69, as well as CYP2B65
(rs3211371 (R487C)) did not show genome-wide significant results, but were in high LD with
the top-SNP in CYP2B6 (rs7260329) (S9 Fig). Further, rs7260329 shows modest LD with our
independent SNPs rs56113850 (D’ = 0.40), esv2663194 (D’ = 0.65), and rs12461964 (D’ =
0.43), but not with rs113288603 (D’ = 0.04); thus, it is unclear whether the detected association
simply reflects LD with the independent variants residing in CYP2A6.
The interpretation of the detected CYP2A7 association is challenging, as the possible role of
CYP2A7 in nicotine metabolism is unknown. Our top SNP in CYP2A7 (rs28602288) is located
within a predicted promoter region. It is plausible that the association between rs28602288 and
NMR reflects the regulation of CYP2A612 (a hybrid allele of CYP2A6 and CYP2A7) or similar
constructs, such as the one generated by the 32 kb deletion tagged by esv2663194, rather than
implies a role for CYP2A7 in nicotine clearance. Rs28602288 is in LD with all of the indepen-
dent variants (D’ = 0.67–1.00).
Two additional interesting genes were highlighted. Egl-9 Family Hypoxia-Inducible Factor 2
(EGLN2) is a key component of the oxygen-sensing pathway that regulates the expression of
various downstream genes, and responses e.g. to carbon monoxide (CO) and cigarette smoke
exposure. In a recent study, EGLN2 was associated with CPD and breath CO independent of
CYP2A6, although it was not associated with nicotine metabolism [62]. The top-SNP in
EGLN2 (rs76443752) is in LD with all of the independent CYP2A6 variants (D’ = 0.67–1.00).
Another potentially interesting candidate is Numb Homolog (Drosophila)-Like (NUMBL)
which encodes a protein that maintains progenitor cells during cortical neurogenesis [63] and
has previously been implicated in lung cancer [64, 65]. The top-SNP in NUMBL (rs4802082) is
in LD with all of the independent variants (D’ = 0.48–0.96).
We constructed wGRS using the independent 19q13.2 SNPs and tested whether the wGRS
predicts smoking behavior in two independent Finnish samples. The wGRS constructed of
major alleles (increasing the metabolism rate) was associated with increased smoking quantity.
This is in line with previous evidence of faster metabolizers smoking more [66]. Adding the
rs56113850rs113288603 interaction term to the wGRS analyses did not improve model fit,
suggesting that the simpler model with main effects was sufficient. Our unadjusted wGRS
results for current vs. former smoking suggested that major alleles that associate with faster
metabolism associate with increased odds of being a former smoker; after adjustment and
exclusion for potential confounders the wGRS result no longer was significant. Although the
sample size decreased, the confidence intervals did not significantly increase, suggesting that
the change in results is due to reduced confounding rather than reduced power. Many clinical
trials and epidemiological studies indicate that slow metabolizers quit more often than normal
metabolizers [20, 67, 68]. Possibly our wGRS does not capture all the relevant aspects of mea-
sured NMR or the cross-sectional nature of the FINRISK smoking status data did not permit
us to fully replicate earlier findings.
We followed up the 719 genome-wide significant SNPs by meQTL analyses in order to
annotate their potential functional consequence. As smoking is known to induce significant
changes in methylation patterns [69], only cotinine-verified current smokers (cotinine10ng/
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ml) were included in the analyses. Several SNPs showed significant association with methyla-
tion values of 16 CpG sites located within the target region. The 16 CpG sites overlap with rele-
vant genes, such as members of the cytochrome P450 gene family (CYP2F1 and CYP2A7) and
EGLN2. According to CIT, methylation in one CpG site mediate the effect of SNPs on the vari-
ance observed in NMR. This CpG site (tagged by cg08551532) is located in DLL3, which is
involved in neurogenesis via its role in the Notch signaling pathway [70]. Further, DLL3 has
been shown to be silenced by methylation in human hepatocellular carcinoma (HCC), leading
to restricted growth of cancer cells [71]. Expression of NOTCH3, encoding for a receptor for
DLL3, has been shown to be influenced by cigarette smoke [72]. The potential mechanism how
DLL3may affect nicotine metabolism remains to be determined.
To our knowledge this is the first GWAS of NMR reported to date. Despite a relatively small
sample size (N = 1518), we detected a multitude of genome-wide significant signals on
19q13.2, highlighting the power of informative biomarkers in GWAS and demonstrating the
power of Finnish population samples to identify novel genes even with a modest sample size.
Our genetic and epigenetic analyses enclosed several genes as potential players in regulating
NMR. Four members of the cytochrome P450 gene family (CYP2A6, CYP2B6, CYP2A7, and
CYP2F1) were highlighted, although only CYP2A6 encompassed independent signals. Three
additional highlighted genes (DLL3, NUMBL, and EGLN2) are functionally linked according to
the GeneMania database (http://www.genemania.org/), suggesting that an interplay between
these genes may influence NMR. Future studies are needed to elucidate the potential role of
these genes in NMR. The detected novel CYP2A6 variants explain a strikingly large fraction of
variance (up to 31%) in NMR in the current sample, suggesting that they tag both known and
unidentified functional variants. The population-attributable effect of the detected independent
variants is thus far greater than that of the four functional variants frequently genotyped in
Caucasians (CYP2A62, 4, 9, and 12). Further, we enclose evidence for plausible epigenetic
mechanisms on 19q13.2 influencing NMR.
Supporting Information
S1 Fig. Distribution of nicotine metabolite ratio (NMR) before and after transformation.
(A) Distribution of NMR in the FinnTwin sample, (B) distribution of rank transformed NMR
in the FinnTwin sample, (C) distribution of NMR in the YFS sample, (D) distribution of rank
transformed NMR in the YFS sample, (E) distribution of NMR in the FINRISK2007 sample,
(F) distribution of rank transformed NMR in the FINRISK2007 sample.
(TIF)
S2 Fig. Interquartile range (IQR) of normalized methylation beta values among 1424 CpG
sites within the 19q13.2 target region (chr19:39046965–44210562, according to GRCh37/
hg19). A total of 158 probes exceeded the threshold of interquartile range0.05 and were
selected for mQTL analyses.
(TIF)
S3 Fig. LD structure of CYP2A6 with ±10 kb flanking regions. (A) Pairwise D’, (B) Pairwise
R2. Block boundaries were defined by the ‘solid spine of LD’ option of Haploview [45].
(TIF)
S4 Fig. LD structure of CYP2A6 (genome-wide significant SNPs only). (A) Pairwise D’, (B)
Pairwise R2. Block boundaries were defined by the ‘solid spine of LD’ option of Haploview
[45].
(TIF)
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S5 Fig. LD structure of CYP2A6 (independent genome-wide significant SNPs and potential
functional SNPs regardless of their p-value). (A) Pairwise D’, (B) Pairwise R2. The second
independent SNP (rs113288603) is also included, although it was not genome-wide significant
in the GWAS meta-analysis but only in analyses conditioned on the top-SNP (rs56113850).
Block boundaries were defined by the ‘solid spine of LD’ option of Haploview [45].
(TIF)
S6 Fig. Distribution of NMR and rank transformed NMR values among different genotype
groups of the four independent SNPs and the five known CYP2A6 alleles in the Young
Finns Study (YFS) sample (N = 714). The exact number of subjects in each comparison varies
depending on the number of subjects with non-missing data for that SNP. Number of subjects
is indicated for each genotype group.
(TIF)
S7 Fig. LD structure of CYP2B6. (A) Pairwise D’, (B) Pairwise R2. Block boundaries were
defined by the ‘solid spine of LD’ option of Haploview [45].
(TIF)
S8 Fig. LD structure of CYP2B6 (genome-wide significant SNPs only). (A) Pairwise D’, (B)
Pairwise R2. Block boundaries were defined by the ‘solid spine of LD’ option of Haploview
[45].
(TIF)
S9 Fig. LD structure of CYP2B6 (the top-SNP and potential functional SNPs regardless of
their p-value). (A) Pairwise D’, (B) Pairwise R2. Rs2279343 (CYP2B64) was not available in
the FINRISK data used for LD calculations. Block boundaries were defined by the ‘solid spine
of LD’ option of Haploview [45].
(TIF)
S1 Table. Estimated power of the meta-analysis sample (N = 1518) to detect signals at the
p<5E-08 significance threshold and LD(r2) = 0.8 between the causal allele and the marker
allele, with a range of MAFs and effect sizes. Effective sample size was N = 1486 after
accounting for interclass correlation within the 78 DZ pairs included in the FinnTwin sample.
(XLSX)
S2 Table. Cohort-specific GWAS and meta-analysis results for the 719 genome-wide signif-
icant SNPs on 19q13.2.
(XLSX)
S3 Table. Cohort-specific GWAS and meta-analysis results for all CYP2A6 SNPs included
in our data set.
(XLSX)
S4 Table. Linkage disequilibrium (D’ and R2) between the four independent SNPs and the
five characterized CYP2A6 alleles included in the data set.
(XLSX)
S5 Table. Comparison of results obtained from GWAS meta-analysis and analysis condi-
tioned on the top-SNP (rs56113850) for the independent SNPs and for the five character-
ized CYP2A6 alleles included in the data.
(XLSX)
S6 Table. Methylation quantitative trait loci (meQTL) results. Analyses were done for 158
CpG sites and 719 SNPs on 19q13.2. Results are shown only for the 16 CpG sites for which an
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FDR corrected p-value below 0.05 (highlighted) was obtained. The 16 CpG sites have 173 SNPs
significantly associating with them.
(XLSX)
S7 Table. Annotation of the 16 CpG sites highlighted in meQTL.
(XLSX)
S8 Table. Causal inference test results shown for one CpG site (cg08551532 inDLL3) in
which methylation mediates the effect of SNPs on NMR. The other 15 CpG sites highlighted
in meQTL analyses did not show evidence of mediation.
(XLSX)
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